EUVIMEDEUVIMED entdecken
Crossref

Palliative Radiotherapy Near the End of Life: An Analysis of Factors Influencing the Administration of Radiotherapy in Advanced Tumor Disease

Nguyen-Son Le iD, Asli Zeybek, Klaus Hackner, Cornelia Gallauner iD, Josef Singer iD, Felix Schragel iD, Petra Georg, Sandra Gottsauner-Wolf, Martin Pecherstorfer, Gudrun Kreye iD

JCO Global Oncology · 2025

DOI: 10.1200/go-24-00500 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Global Oncology, 2025. Verfasst von Nguyen-Son Le und 9 weiteren Autor:innen. Beteiligte Einrichtung: Karl Landsteiner University of Health Sciences, Dr Karl-Dorrek-Straße 30, Krems, Austria. Hauptthemen laut MEDLINE: Palliative Care, Neoplasms, Terminal Care. Die Arbeit nennt 40 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Palliative radiotherapy (PRT) toward the end of life (EOL) in advanced tumor disease is contentious. Although EOL RT can alleviate cancer-related symptoms, relief typically occurs weeks to months after treatment, potentially compromising the quality of life of patients during the final stages. This study aims to assess factors influencing the decision-making process regarding EOL RT. MATERIALS AND METHODS This retrospective study of a real-world cohort included 684 consecutive patients with a diagnosis of a solid tumor who died between 2017 and 2021. In these patients, factors potentially influencing the administration of EOL RT were analyzed. RESULTS Of the 684 patients, 164 received PRT, with 60 (36.6%) receiving EOL RT within the last 30 days of life. The median time from the last RT session to death was 55 days. Significant factors influencing EOL RT administration were age ≤65 years (odds ratio [OR], 1.75 [95% CI, 1.02 to 3.01]), Union for International Cancer Control stage IV (OR, 2.77 [95% CI, 1.41 to 5.46]), lung cancer (OR, 2.16 [95% CI, 1.00 to 4.68]), palliative care referral (OR, 1.80 [95% CI, 0.98 to 3.30]), systemic anticancer treatment ≤30 days before death (OR, 1.87 [95% CI, 1.05 to 3.33]), and Eastern Cooperative Oncology Group performance status ≥2 (OR, 3.73 [95% CI, 1.88 to 7.40]). Furthermore, RT near the EOL was more likely administered at multiple sites (OR, 2.08 [95% CI, 1.00 to 4.29]) and with ≤5 fractions (OR, 2.37 [95% CI, 1.23 to 4.57]), while being associated with lower response rates (OR, 0.43 [95% CI, 0.21 to 0.86]) and increased therapy discontinuation (OR, 4.40 [95% CI, 1.45 to 13.37]). CONCLUSION These findings highlight varying RT patterns influenced by specific factors, demonstrating the complexity of EOL treatment decisions in advanced cancer care. Identifying key factors for personalized, patient-centered EOL RT decisions warrants further investigation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Palliative CareNeoplasmsTerminal CareHumansFemaleMaleRetrospective StudiesAgedMiddle AgedAged, 80 and overQuality of LifeAdult

Autor:innen und Institutionen

  • Karl Landsteiner University of Health Sciences, Dr Karl-Dorrek-Straße 30, Krems, Austria.
  • Division of Palliative Care, Department of Internal Medicine 2, University Hospital Krems, Karl Landsteiner University of Health Sciences, Krems, Austria.
  • Department of Internal Medicine, Kantonsspital Zug, Zug, Switzerland.
  • Division of Pneumology, University Hospital Krems, Karl Landsteiner University of Health Sciences, Krems, Austria.
  • Department of Internal Medicine 1, University Hospital St Pölten, Karl Landsteiner University of Health Sciences, St Pölten, Austria.
  • Department of Radiotherapy-Radiation Oncology, University Hospital Krems, Karl Landsteiner University of Health Sciences, Krems, Austria.

ORCID-Profile: Nguyen-Son Le, Cornelia Gallauner, Josef Singer, Felix Schragel, Gudrun Kreye

Zitieren

APA

Le, N. S., Zeybek, A., Hackner, K., Gallauner, C., Singer, J., Schragel, F., Georg, P., Gottsauner-Wolf, S., Pecherstorfer, M., & Kreye, G. (2025). Palliative Radiotherapy Near the End of Life: An Analysis of Factors Influencing the Administration of Radiotherapy in Advanced Tumor Disease. JCO Global Oncology. https://doi.org/10.1200/go-24-00500

Vancouver

Le NS, Zeybek A, Hackner K, Gallauner C, Singer J, Schragel F, et al. Palliative Radiotherapy Near the End of Life: An Analysis of Factors Influencing the Administration of Radiotherapy in Advanced Tumor Disease. JCO Global Oncology. 2025. doi:10.1200/go-24-00500

BibTeX
@article{Le2025,
  author = {Le, Nguyen-Son and Zeybek, Asli and Hackner, Klaus and Gallauner, Cornelia and Singer, Josef and Schragel, Felix and Georg, Petra and Gottsauner-Wolf, Sandra and Pecherstorfer, Martin and Kreye, Gudrun},
  title = {Palliative Radiotherapy Near the End of Life: An Analysis of Factors Influencing the Administration of Radiotherapy in Advanced Tumor Disease},
  journal = {JCO Global Oncology},
  year = {2025},
  doi = {10.1200/go-24-00500}
}
Kostenlos starten →